Leerink Partnrs Brokers Lift Earnings Estimates for Certara

Certara, Inc. (NASDAQ:CERT) – Research analysts at Leerink Partnrs upped their Q1 2025 earnings per share estimates for shares of Certara in a research note issued on Monday, April 14th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.07 per share for the quarter, up from their previous estimate of $0.05. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Several other research analysts have also weighed in on CERT. KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday. Barclays dropped their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Finally, William Blair reaffirmed a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

Certara Stock Performance

NASDAQ CERT opened at $14.15 on Wednesday. The firm has a market capitalization of $2.28 billion, a P/E ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm’s fifty day moving average price is $11.62 and its two-hundred day moving average price is $11.44. Certara has a 1 year low of $8.64 and a 1 year high of $17.94.

Institutional Investors Weigh In On Certara

Institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC bought a new position in Certara during the 1st quarter worth $120,000. SG Americas Securities LLC grew its holdings in shares of Certara by 350.1% during the 1st quarter. SG Americas Securities LLC now owns 69,727 shares of the company’s stock worth $690,000 after purchasing an additional 54,235 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Certara by 16.2% in the first quarter. Harbor Capital Advisors Inc. now owns 20,294 shares of the company’s stock worth $201,000 after purchasing an additional 2,834 shares during the period. Portside Wealth Group LLC acquired a new position in Certara in the first quarter valued at about $104,000. Finally, Kopion Asset Management LLC lifted its position in Certara by 8.0% during the first quarter. Kopion Asset Management LLC now owns 600,159 shares of the company’s stock worth $5,942,000 after purchasing an additional 44,516 shares during the period. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.